Articles tagged "Hepatocellular carcinoma"

2019 American Transplant Congress
The Rapidly Aging Population of Liver Transplant Patients with Hepatocellular Carcinoma
J. B. Rubin, G. Cullaro, N. Mehta, J. C. Lai
Division of Gastroenterology & Hepatology, UCSF, San Francisco, CA
*Purpose: Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related mortality in the US and a leading indication for liver transplant (LT). Direct acting…
2019 American Transplant Congress
Halt-hcc At The Time Of Listing Is Superior To Other Allocation Metrics At Predicting Waitlist Dropout; An Srtr Analysis
J. C. McVey¹, K. Sasaki¹, D. J. Firl², C. M. Miller¹, K. Hashimoto¹, C. Quintini¹, F. N. Aucejo¹
¹Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, ²Department of General Surgery, Duke University, Durham, NC
*Purpose: A recently developed liver allocation metric, Hazard Associated with Liver Transplant for Hepatocellular Carcinoma (HALT-HCC), has been shown to predict post-transplantation survival and recurrence.…
2019 American Transplant Congress
Impact of Previous Hepatic Resection on the Outcome of Liver Transplantation: A Case-Control Analysis
M. Serenari, M. Paterno, A. D. Pinna, M. Ravaioli, E. Prosperi, M. Del Gaudio, C. Zanfi, V. Bertuzzo, G. Frascaroli, M. Cescon
University of Bologna, Bologna, Italy
*Purpose: The aim of this study was to investigate the impact of HR on the outcome of LT.*Methods: Data of patients treated by LT between…
2019 American Transplant Congress
Treatment Modality Affects Outcomes of Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A US Multicenter Analysis of 2786 Patients
P. Tabrizian¹, K. J. Halazun², M. L. Holzner¹, N. Mehta³, F. Y. Yao³, J. Roberts³, J. C. Emond⁴, B. Samstein², R. S. Brown⁴, S. Florman¹, M. E. Schwartz¹, M. M. Doyle⁵, W. C. Chapman⁵, M. Najjar⁴, R. W. Busuttil⁶, V. G. Agopian⁶
¹Transplant, Mount Sinai Medical Center, New York, NY, ²Transplant, Weill Cornell Medicine, New York, NY, ³Transplant, University of California San Francisco, San Francisco, CA, ⁴Transplant, Columbia University Medical Center, New York, NY, ⁵Transplant, Washington University School of Medicine, St Louis, MO, ⁶Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) has a poor prognosis. We evaluated the impact of treatment modalities on post-recurrence survival.*Methods: Adult patients…
2019 American Transplant Congress
Whole-Exome Sequencing Identifies PMS1 and DYRK1A Genes Contributing to Occurrence of Liver Cancer
Y. Zhao, B. Yang, D. Chen, L. Wei, Z. Chen
Tongji hospital, Huazhong university, Organ Transplantation, Wuhan, China
*Purpose: Liver cancer is one of the most frequent cancers in China and the accurate landscape of liver cancer, especially of HBV-infected liver cancer in…
2019 American Transplant Congress
Clinical Outcomes of Patients with Portal Vein Tumor Thrombi after Living Donor Liver Transplantation
D. Kim
Surgery, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: Patient selection criteria for living donor liver transplantation(LDLT) with hepatocellular carcinoma are generally wider than those for deceased donor liver transplantation. It is widely…
2019 American Transplant Congress
Peri-Operative Basiliximab is Not Associated with Post-Transplant Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients
D. Salerno¹, N. Lange¹, E. Simoneau², C. Sammons³, D. Bley¹, R. S. Brown Jr⁴, J. Emond², K. Halazun⁵
¹Pharmacy, NewYork-Presbyterian Hospital, New York, NY, ²Surgery, Columbia University Irving Medical Center, New York, NY, ³Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Medicine, Weill Cornell Medicine, New York, NY, ⁵Surgery, Weill Cornell Medicine, New York, NY
*Purpose: The optimal immunosuppression for liver transplant recipients (LTR) with hepatocellular carcinoma (HCC) is unknown. Basiliximab, an interleukin-2 receptor antagonist (IL-2RA), confers immunosuppression for LTR…
2019 American Transplant Congress
Long Term Outcomes of Patients Transplanted for Hepatocellular Carcinoma with Human Immunodeficiency Virus Infection
R. Gedaly-Eidelman, E. Chacon, P. Eman, M. Gupta, J. Berger, A. El-Husseini, X. Mei, F. Marti, L. Turcios, M. Shah
University of Kentucky, Lexington, KY
*Purpose: Several studies have reported that HIV+ patients are 4-6 times more likely to develop HCC than uninfected individuals. Our aim was to assess outcomes…
2019 American Transplant Congress
Outcomes of Liver Transplantation for Hepatocellular Carcinoma in Septuagenarians
M. Najjar¹, K. Bruestle¹, P. Jiang¹, E. Lieberman¹, R. Hwang¹, A. Mathur¹, E. C. Verna¹, A. Griesemer¹, B. Samstein², T. Kato¹, Y. M. Saenger¹, K. J. Halazun², J. C. Emond¹
¹Columbia University Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: The impact of advanced age on liver transplantation (LT) for hepatocellular carcinoma (HCC) has not been well studied. We sought to compare post-OLT survival…
2019 American Transplant Congress
Policy Changes in Liver Graft Allocation for Hepatocellular Carcinoma in the USA: Improved Survival for African American Recipients
M. Molinari¹, D. Jorgensen¹, A. Tevar¹, C. Hughes¹, A. Humar¹, N. Jonassaint²
¹Surgery, University of Pittsburgh Medical Centre, Pittsburgh, PA, ²Medicine, University of Pittsburgh Medical Centre, Pittsburgh, PA
*Purpose: To evaluate the effect of policy changes in liver graft allocation for hepatocellular carcinoma (HCC) on the overall survival of patients of different ethnicities…